Additionally, we also pooled the available data of 5-year OS rates between EGFR-TKI group and non-EGFR-TKI group for patients with stage IB-III NSCLC, an improvement of 5-year OS rate could be seen in the EGFR-TKI group (RR, 0.89, 95% CI, 0.82–97, P = 0.008, Fig. 3B), while the difference in the 5-year OS rate between the two groups was not significant when we included the ADAURA trial (RR, 0.90, 95% CI, 0.77–1.04, P = 0.162, Fig. S3). This evidence concerns the gene EGFR and non-small cell lung carcinoma.